EQ

Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease

Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

Equillium to Present at the JMP Securities Life Sciences Conference

Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association